Cytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion

Description:
GBI Research, the leading business intelligence provider, has released its latest research, “Cytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion”, which provides insights into the cytotoxic therapies market until 2017 for eight oncology indications. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

The report provides an in-depth analysis of the major oncology indications, including breast cancer, cervical cancer, colorectal cancer, non-Hodgkin lymphoma, head and neck cancer, non-small cell lung cancer, ovarian cancer and prostate cancer. The report examines the global oncology disease treatment usage patterns. In addition, the geographical distribution of cytotoxic therapies and markets across the US, the top five countries of Europe and Japan is provided in the report. The report also includes insights into the cytotoxic therapies R&D product pipeline and explores the competitive landscape, including major players in the cytotoxic therapies market. Finally, the report also includes analysis on Mergers and Acquisitions (M&As) and licensing agreements that have taken place in the cytotoxic therapies market.

In 2010, the cytotoxic therapies market for eight major oncology indications was estimated at $10.1 billion, indicating a compound annual growth rate (CAGR) of 5.8% since 2002. GBI Research forecasts the market to decline marginally at a CAGR of (0.1%) between 2010 and 2017, to record a sales value of $10.1 billion by 2017. The eight indications covered are breast cancer, cervical cancer, colorectal cancer, head and neck cancer, non-Hodgkin lymphoma, non-small cell lung cancer, ovarian cancer, and prostate cancer. The growth in major markets such as the US, the top five countries of Europe, and Japan, was driven mainly by the increasing prevalence and prescription population, and the combination of cytotoxic medicines with biologics, while the overall decline in market value is a result of patent expiries in the forecast period and subsequent reduction in annual cost of therapy.

The US was the leading geography, with an estimated sales value of $5.5 billion and an approximate share of 55%. The US market is expected to decline at a rate of (1.7%) between 2010 and 2017, to record a sales value of $4.9 billion in 2017. The top five countries of Europe together contributed to sales worth $3.3 billion in 2010, accounting for an approximate global share of 32.4%. The top five countries of Europe are expected to record sales worth $3.8 billion by the year 2017, registering a growth rate of 2%. Japan, in 2010, contributed $1.3 billion to the global market, increasing at a CAGR of 4.5% from 2002. It accounts for an approximate share of 12.6%. Decreasing at a rate of (1.1%) between 2010 and 2017, the market is expected to record sales worth $1.2 billion by 2017.

Scope

- Data and analysis on the cytotoxic therapies market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.

- Annualized market data for the cytotoxic therapies market from 2002 to 2010, with forecasts to 2017.

- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume, and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.

- Key drivers and restraints that have had a significant impact on the market.

- The competitive landscape of the global cytotoxic therapies market, including top companies benchmarking. The key companies studied in this report are Sanofi, Eli Lilly, Takeda Pharmaceuticals and Roche

- Key M&A activities and licensing agreements that took place in 2008 and 2011 in the cytotoxic therapies
Reasons to buy

- Align your product portfolio to the markets with high growth potential.
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Devise a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

Contents:

1.1 List of Tables
1.2 List of Figures

2 Cytotoxic Therapies Market to 2017 - Introduction
2.1 GBI Research Report Guidance

3 Cytotoxic Therapies Market to 2017 - Market Overview
3.1 Introduction
3.1.1 Revenue
3.1.2 Annual Cost of Therapy
3.1.3 Treatment Usage Pattern
3.2 Drivers and Barriers for the Global Cytotoxic Therapies Market
3.2.1 Drivers for the Global Cytotoxic Therapies Market
3.2.2 Barriers for the Global Cytotoxic Therapies Market

4 Cytotoxic Therapies Market to 2017 - Geographical Landscape
4.1 Geographical Segmentation
4.2 The US
4.2.1 Revenue
4.2.2 Annual Cost of Therapy
4.2.3 Treatment Usage Pattern
4.2.4 Drivers and Barriers for the Cytotoxic Therapies Market in the US
4.3 Top Five Countries of Europe
4.3.1 Revenue
4.3.2 Annual Cost of Therapy
4.3.3 Treatment Usage Pattern
4.3.4 Drivers and Barriers for the Cytotoxic Therapies Market in the Top Five Countries of Europe
4.4 Japan
4.4.1 Revenue
4.4.2 Annual Cost of Therapy
4.4.3 Treatment Usage Pattern
4.4.4 Drivers and Barriers for the Cytotoxic Therapies Market in Japan

5 Cytotoxic Therapies Market to 2017 - Therapeutic Landscape
5.1 Breast Cancer
5.1.1 Introduction
5.1.2 Survival Rates by Stage
5.1.3 Symptoms
5.1.4 Treatment Flow
5.1.5 Revenue
5.8.6 Annual Cost of Therapy
5.8.7 Treatment Usage Pattern
5.8.8 Drivers and Barriers

6 Cytotoxic Therapies Market to 2017 - Pipeline Analysis
6.1 Introduction
6.2 Cytotoxic Therapies Market - Pipeline Assessment by Indication
  6.2.1 Breast Cancer
  6.2.2 Cervical Cancer
  6.2.3 Colorectal Cancer
  6.2.4 Head and Neck Cancer
  6.2.5 Non-Hodgkin Lymphoma
  6.2.6 Non-Small Cell Lung Cancer
  6.2.7 Ovarian Cancer
  6.2.8 Prostate Cancer
6.3 Profiles of Promising Molecules in the Cytotoxic Therapies Market
  6.3.1 Eniluracil (ADH300004)
  6.3.2 Karenitecin
  6.3.3 Vintafolide (EC145)
  6.3.4 Tavocept

7 Cytotoxic Therapies Market to 2017 - Competitive Landscape
7.1 Sanofi
  7.1.1 Company Overview
  7.1.2 Marketed Products
  7.1.3 SWOT Analysis
7.2 Eli Lilly & Company
  7.2.1 Company Overview
  7.2.2 Marketed Products
  7.2.3 SWOT Analysis
7.3 Takeda Pharmaceutical Company Ltd.
  7.3.1 Company Overview
  7.3.2 Marketed Products
  7.3.3 SWOT Analysis
7.4 F. Hoffmann-La Roche Ltd.
  7.4.1 Company Overview
  7.4.2 Marketed Products
  7.4.3 SWOT Analysis

8 Cytotoxic Therapies Market to 2017 - Strategic Consolidations
8.1 Deals by Type
8.2 Deals by Indication
8.3 Mergers and Acquisitions
  8.3.1 Segmentation by Year
  8.3.2 Segmentation by Value
  8.3.3 Segmentation by Geography
8.3.4 Major Merger and Acquisition Deals
8.4 Co-Development Deals
  8.4.1 Segmentation by Year
  8.4.2 Segmentation by Geography
8.4.3 Major Co-Development Deals
8.5 Licensing Deals
  8.5.1 Segmentation by Year
  8.5.2 Segmentation by Value
  8.5.3 Segmentation by Geography
8.5.4 Major Licensing Deals

9 Cytotoxic Therapies Market to 2017 - Appendix
9.1 Market Definitions
9.2 Abbreviations
9.3 Sources
9.4 Research Methodology
9.4.1 Coverage
Table 46: Cytotoxic Therapies Market, Global, Cervical Cancer, Treatment Usage Pattern, Population ('000), 2002-2010
Table 47: Cytotoxic Therapies Market, Global, Cervical Cancer, Treatment Usage Pattern, Population ('000), 2010-2017
Table 48: Cytotoxic Therapies Market, Global, Colorectal Cancer, Cancer Categorized by Disease Stage
Table 49: Cytotoxic Therapies Market, Global, Colorectal Cancer, Stage Distribution and Five-Year Relative Survival by Stage at Diagnosis for Patients in the US (%), 2001-2007
Table 50: Cytotoxic Therapies Market, Global, Colorectal Cancer, Revenue ($bn), 2002-2010
Table 51: Cytotoxic Therapies Market, Global, Colorectal Cancer, Revenue Forecasts ($bn), 2010-2017
Table 52: Cytotoxic Therapies Market, Global, Colorectal Cancer, Geographical Segmentation ($m), 2002-2010
Table 53: Cytotoxic Therapies Market, Global, Colorectal Cancer, Geographical Segmentation ($m), 2010-2017
Table 54: Cytotoxic Therapies Market, Global, Colorectal Cancer, Annual Cost of Therapy ($), 2002-2010
Table 55: Cytotoxic Therapies Market, Global, Colorectal Cancer, Annual Cost of Therapy ($), 2010-2017
Table 56: Cytotoxic Therapies Market, Global, Colorectal Cancer, Treatment Usage Pattern, Population ('000), 2002-2010
Table 57: Cytotoxic Therapies Market, Global, Colorectal Cancer, Treatment Usage Pattern, Population ('000), 2010-2017
Table 58: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Staging, 2011
Table 59: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Stage Distribution and Survival For Patients in the US (%), 1998-2001
Table 60: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Revenue ($m), 2002-2010
Table 61: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Revenue Forecasts ($m), 2010-2017
Table 62: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Geographical Segmentation ($m), 2002-2010
Table 63: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Geographical Segmentation ($m), 2010-2017
Table 64: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Annual Cost of Therapy ($), 2002-2010
Table 65: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Annual Cost of Therapy ($), 2010-2017
Table 66: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Treatment Usage Pattern, Population ('000), 2002-2010
Table 67: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Treatment Usage Pattern, Population ('000), 2010-2017
Table 68: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Cancer Categorized by Disease Stage
Table 69: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Stage Distribution and 5-Year Survival Rates by Stage at Diagnosis for Patients in the US (%), 2001-2007
Table 70: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Revenue ($m), 2002-2010
Table 71: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Revenue Forecasts ($m), 2010-2017
Table 72: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Geographical Segmentation ($m), 2002-2010
Table 73: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Geographical Segmentation ($m), 2010-2017
Table 74: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Annual Cost of Therapy ($), 2002-2010
Table 75: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Annual Cost of Therapy ($), 2010-2017
Table 76: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Treatment Usage Pattern, Population ('000), 2002-2010
Table 77: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Treatment Usage Pattern, Population ('000), 2010-2017
Table 78: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Cancer Categorized by Disease Stage
Table 79: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Stage Distribution and Survival for Lung Cancer Patients in the US (%), 2000-2007
Table 80: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Revenue ($m), 2002-2010
Table 81: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Revenue Forecasts ($m), 2010-2017
Table 82: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Geographical Segmentation ($m), 2002-2010
Table 83: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Geographical Segmentation ($m), 2010-2017
Table 84: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Annual Cost of Therapy ($), 2002-2010
Table 85: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Annual Cost of Therapy ($), 2010-2017
Table 86: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Treatment Usage Pattern, Population ('000), 2002-2010
Table 87: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Treatment Usage Pattern, Population ('000), 2010-2017
Table 88: Cytotoxic Therapies Market, Global, Ovarian Cancer, Surgical Staging, 2011
Table 89: Cytotoxic Therapies Market, Global, Ovarian Cancer, Stage Distribution and Survival for Patients in the US (%), 2001-2007
Table 90: Cytotoxic Therapies Market, Global, Ovarian Cancer, Post-Operative Treatment, 2011
Table 91: Cytotoxic Therapies Market, Global, Ovarian Cancer, Revenue ($m), 2002-2010
Table 92: Cytotoxic Therapies Market, Global, Ovarian Cancer, Revenue Forecasts ($m), 2010-2017
Table 93: Cytotoxic Therapies Market, Global, Ovarian Cancer, Geographical Segmentation ($m), 2002-2010
Table 94: Cytotoxic Therapies Market, Global, Ovarian Cancer, Geographical Segmentation ($m), 2010-2017
Table 95: Cytotoxic Therapies Market, Global, Ovarian Cancer, Annual Cost of Therapy ($), 2002-2010
Table 96: Cytotoxic Therapies Market, Global, Ovarian Cancer, Annual Cost of Therapy ($), 2010-2017
Table 97: Cytotoxic Therapies Market, Global, Ovarian Cancer, Treatment Usage Pattern, Population ('000), 2002-2010
Table 98: Cytotoxic Therapies Market, Global, Ovarian Cancer, Treatment Usage Pattern, Population ('000), 2010-2017
Table 99: Cytotoxic Therapies Market, Global, Prostate Cancer, Cancer Characterized by Disease Stage
Table 100: Cytotoxic Therapies Market, Global, Prostate Cancer, Stage Distribution and Survival for Patients in the US (%), 2000-2007
Table 101: Cytotoxic Therapies Market, Global, Prostate Cancer, Revenue ($m), 2002-2010
Table 102: Cytotoxic Therapies Market, Global, Prostate Cancer, Revenue Forecasts ($m), 2010-2017
Table 103: Cytotoxic Therapies Market, Global, Prostate Cancer, Geographical Segmentation ($m), 2002-2010
Table 104: Cytotoxic Therapies Market, Global, Prostate Cancer, Geographical Segmentation ($m), 2010-2017
Table 105: Cytotoxic Therapies Market, Global, Prostate Cancer, Annual Cost of Therapy ($), 2002-2010
Table 106: Cytotoxic Therapies Market, Global, Prostate Cancer, Annual Cost of Therapy ($), 2010-2017
Table 107: Cytotoxic Therapies Market, Global, Prostate Cancer Treatment Usage Pattern, Population ('000), 2002-2010
Table 108: Cytotoxic Therapies Market, Global, Prostate Cancer Treatment Usage Pattern, Population ('000), 2010-2017
Table 109: Cytotoxic Therapies Market, Global, Breast Cancer, Phase III Pipeline, 2011
Table 110: Cytotoxic Therapies Market, Global, Breast Cancer, Phase II Pipeline, 2011
Table 111: Cytotoxic Therapies Market, Global, Breast Cancer, Phase I Pipeline, 2011
Table 112: Cytotoxic Therapies Market, Global, Breast Cancer, Pre-Clinical Phase Pipeline, 2011
Table 113: Cytotoxic Therapies Market, Global, Breast Cancer, Discovery Phase Pipeline, 2011
Table 114: Cytotoxic Therapies Market, Global, Breast Cancer, Geographical Segmentation ($m), 2002-2010
Table 115: Cytotoxic Therapies Market, Global, Breast Cancer, Geographical Segmentation ($m), 2010-2017
Table 116: Cytotoxic Therapies Market, Global, Breast Cancer, Annual Cost of Therapy ($), 2002-2010
Table 117: Cytotoxic Therapies Market, Global, Breast Cancer, Annual Cost of Therapy ($), 2010-2017
Table 118: Cytotoxic Therapies Market, Global, Breast Cancer, Treatment Usage Pattern, Population ('000), 2002-2010
Table 119: Cytotoxic Therapies Market, Global, Breast Cancer Treatment Usage Pattern, Population ('000), 2010-2017
Table 120: Cytotoxic Therapies Market, Global, Colorectal Cancer, Phase III Pipeline, 2011
Table 121: Cytotoxic Therapies Market, Global, Colorectal Cancer, Phase II Pipeline, 2011
Table 122: Cytotoxic Therapies Market, Global, Colorectal Cancer, Phase I Pipeline, 2011
Table 123: Cytotoxic Therapies Market, Global, Colorectal Cancer, Pre-Clinical Phase Pipeline, 2011
Table 124: Cytotoxic Therapies Market, Global, Colorectal Cancer, Discovery Phase Pipeline, 2011
Table 125: Cytotoxic Therapies Market, Global, Colorectal Cancer, Geographical Segmentation ($m), 2002-2010
Table 126: Cytotoxic Therapies Market, Global, Colorectal Cancer, Geographical Segmentation ($m), 2010-2017
Table 127: Cytotoxic Therapies Market, Global, Colorectal Cancer, Annual Cost of Therapy ($), 2002-2010
Table 128: Cytotoxic Therapies Market, Global, Colorectal Cancer, Annual Cost of Therapy ($), 2010-2017
Table 129: Cytotoxic Therapies Market, Global, Colorectal Cancer Treatment Usage Pattern, Population ('000), 2002-2010
Table 130: Cytotoxic Therapies Market, Global, Colorectal Cancer Treatment Usage Pattern, Population ('000), 2010-2017
Table 131: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Phase III Pipeline, 2011
Table 132: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Phase II Pipeline, 2011
Table 133: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Phase I Pipeline, 2011
Table 134: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Pre-Clinical Phase Pipeline, 2011
Table 135: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Discovery Phase Pipeline, 2011
Table 136: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Geographical Segmentation ($m), 2002-2010
Table 137: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Geographical Segmentation ($m), 2010-2017
Table 138: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Annual Cost of Therapy ($), 2002-2010
Table 139: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Annual Cost of Therapy ($), 2010-2017
Table 140: Cytotoxic Therapies Market, Global, Head and Neck Cancer Treatment Usage Pattern, Population ('000), 2002-2010
Table 141: Cytotoxic Therapies Market, Global, Head and Neck Cancer Treatment Usage Pattern, Population ('000), 2010-2017
Table 142: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Phase III Pipeline, 2011
Table 143: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Phase II Pipeline, 2011
Table 144: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Phase I Pipeline, 2011
Table 145: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Pre-Clinical Phase Pipeline, 2011
Table 146: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Discovery Phase Pipeline, 2011
Table 147: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Geographical Segmentation ($m), 2002-2010
Table 148: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Geographical Segmentation ($m), 2010-2017
Table 149: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Annual Cost of Therapy ($), 2002-2010
Table 150: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Annual Cost of Therapy ($), 2010-2017
Table 151: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma Treatment Usage Pattern, Population ('000), 2002-2010
Table 152: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma Treatment Usage Pattern, Population ('000), 2010-2017
Table 153: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Phase III Pipeline, 2011
Table 154: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Phase II Pipeline, 2011
Table 155: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Phase I Pipeline, 2011
Table 156: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Pre-Clinical Phase Pipeline, 2011
Table 157: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Discovery Phase Pipeline, 2011
Table 158: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Geographical Segmentation ($m), 2002-2010
Table 159: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Geographical Segmentation ($m), 2010-2017
Table 160: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Annual Cost of Therapy ($), 2002-2010
Table 161: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Annual Cost of Therapy ($), 2010-2017
Table 162: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer Treatment Usage Pattern, Population ('000), 2002-2010
Table 163: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer Treatment Usage Pattern, Population ('000), 2010-2017
Table 137: Cytotoxic Therapies Market, Global, Ovarian Cancer, Phase I Pipeline, 2011
Table 138: Cytotoxic Therapies Market, Global, Ovarian Cancer, Pre-Clinical Phase Pipeline, 2011
Table 139: Cytotoxic Therapies Market, Global, Ovarian Cancer, Discovery Phase Pipeline, 2011
Table 140: Cytotoxic Therapies Market, Global, Prostate Cancer, Phase III Pipeline, 2011
Table 141: Cytotoxic Therapies Market, Global, Prostate Cancer, Phase II Pipeline, 2011
Table 142: Cytotoxic Therapies Market, Global, Prostate Cancer, Phase I Pipeline, 2011
Table 143: Cytotoxic Therapies Market, Global, Prostate Cancer, Pre-Clinical Phase Pipeline, 2011
Table 144: Cytotoxic Therapies Market, Global, M&A Deals, 2008-2011
Table 145: Cytotoxic Therapies Market, Global, Co-Development Deals, 2008-2011
Table 146: Cytotoxic Therapies Market, Global, Licensing Deals, 2008-2011

1.2 List of Figures
Figure 1: Cytotoxic Therapies Market, Global, Revenue Forecasts ($bn), 2002-2017
Figure 2: Cytotoxic Therapies Market, Global, Branded and Generic Market Share (%), 2010 and 2017
Figure 3: Cytotoxic Therapies Market, Global, Annual Cost of Therapy ($), 2002-2017
Figure 4: Cytotoxic Therapies Market, Global, Treatment Usage Pattern, Population (‘000), 2002-2017
Figure 5: Cytotoxic Therapies Market, Global, Drivers and Barriers
Figure 6: Cytotoxic Therapies Market, Global, Geographical Segmentation ($m), 2002-2017
Figure 7: Cytotoxic Therapies Market, The US, Revenue Forecasts ($bn), 2002-2017
Figure 8: Cytotoxic Therapies Market, The US, Annual Cost of Therapy ($), 2002-2017
Figure 9: Cytotoxic Therapies Market, The US, Treatment Usage Pattern, Population (‘000), 2002-2017
Figure 10: Cytotoxic Therapies Market, The US, Drivers and Barriers
Figure 11: Cytotoxic Therapies Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2002-2017
Figure 12: Cytotoxic Therapies Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2002-2017
Figure 13: Cytotoxic Therapies Market, Top Five Countries of Europe, Treatment Usage Pattern, Population (‘000), 2002-2017
Figure 14: Cytotoxic Therapies Market, Top Five Countries of Europe, Drivers and Barriers
Figure 15: Cytotoxic Therapies Market, Japan, Revenue Forecasts ($m), 2002-2017
Figure 16: Cytotoxic Therapies Market, Japan, Annual Cost of Therapy ($), 2002-2017
Figure 17: Cytotoxic Therapies Market, Japan, Treatment Usage Pattern, Population (‘000), 2002-2017
Figure 18: Cytotoxic Therapies Market, Japan, Drivers and Barriers
Figure 19: Cytotoxic Therapies Market, Global, Breast Cancer, Types of Breast Cancer, 2011
Figure 20: Cytotoxic Therapies Market, Global, Breast Cancer, Treatment Flow Algorithm, Stage 0
Figure 21: Cytotoxic Therapies Market, Global, Breast Cancer, Treatment Flow Algorithm, Stage I and II
Figure 22: Cytotoxic Therapies Market, Global, Breast Cancer, Treatment Flow Algorithm, Stage III
Figure 23: Cytotoxic Therapies Market, Global, Breast Cancer, Treatment Flow Algorithm, Stage IV
Figure 24: Cytotoxic Therapies Market, Global, Breast Cancer, Revenue Forecasts ($m), 2002-2017
Figure 25: Cytotoxic Therapies Market, Global, Breast Cancer, Geographical Segmentation ($m), 2002-2017
Figure 26: Cytotoxic Therapies Market, Global, Breast Cancer, Branded and Generic Market Share (%), 2010 and 2017
Figure 27: Cytotoxic Therapies Market, Global, Breast Cancer, Annual Cost of Therapy ($), 2002-2017
Figure 28: Cytotoxic Therapies Market, Global, Breast Cancer, Treatment Usage Pattern, Population (‘000), 2002-2017
Figure 29: Cytotoxic Therapies Market, Global, Breast Cancer, Drivers and Barriers
Figure 30: Cytotoxic Therapies Market, Global, Cervical Cancer, Revenue Forecasts ($m), 2002-2017
Figure 31: Cytotoxic Therapies Market, Global, Cervical Cancer, Geographical Segmentation ($m), 2002-2017
Figure 32: Cytotoxic Therapies Market, Global, Cervical Cancer, Branded and Generic Market Share (%), 2010 and 2017
Figure 33: Cytotoxic Therapies Market, Global, Cervical Cancer, Annual Cost of Therapy ($), 2002-2017
Figure 34: Cytotoxic Therapies Market, Global, Cervical Cancer, Treatment Usage Pattern, Population (‘000), 2002-2017
Figure 35: Cytotoxic Therapies Market, Global, Cervical Cancer, Drivers and Barriers
Figure 36: Cytotoxic Therapies Market, Global, Colorectal Cancer, Treatment Flow Algorithm, Colon Cancer, Part-1
Figure 37: Cytotoxic Therapies Market, Global, Colorectal Cancer, Treatment Flow Algorithm, Colon Cancer, Part-2
Figure 38: Cytotoxic Therapies Market, Global, Colorectal Cancer, Treatment Flow Algorithm, Rectal Cancer, 2011
Figure 39: Cytotoxic Therapies Market, Global, Colorectal Cancer, Revenue Forecasts ($bn), 2002-2017
Figure 40: Cytotoxic Therapies Market, Global, Colorectal Cancer, Geographical Segmentation ($m), 2002-2017
Figure 41: Cytotoxic Therapies Market, Global, Colorectal Cancer, Branded and Generic Market Share (%), 2010 and 2017
Figure 88: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer R&D Pipeline, 2011
Figure 89: Cytotoxic Therapies Market, Global, Ovarian Cancer R&D Pipeline, 2011
Figure 90: Cytotoxic Therapies Market, Global, Prostate Cancer R&D Pipeline, 2011
Figure 91: Cytotoxic Therapies Market, Competitive Landscape, Sanofi, 2011
Figure 92: Cytotoxic Therapies Market, Competitive Landscape, Sanofi, SWOT, 2011
Figure 93: Cytotoxic Therapies Market, Competitive Landscape, Eli Lilly & Company, 2011
Figure 94: Cytotoxic Therapies Market, Competitive Landscape, Eli Lilly, SWOT, 2011
Figure 95: Cytotoxic Therapies Market, Competitive Landscape, Takeda Pharmaceuticals, 2011
Figure 96: Cytotoxic Therapies Market, Competitive Landscape, Takeda, SWOT, 2011
Figure 97: Cytotoxic Therapies Market, Competitive Landscape, Roche, 2011
Figure 98: Cytotoxic Therapies Market, Competitive Landscape, Hoffmann-La Roche, SWOT, 2011
Figure 99: Cytotoxic Therapies Market, Global, Deals by Type, 2008-2011
Figure 100: Cytotoxic Therapies Market, Global, Deals by Indications, 2008-2011
Figure 101: Cytotoxic Therapies Market, Global, Mergers and Acquisitions, Segment by Year, 2008-2011
Figure 102: Cytotoxic Therapies Market, Global, Mergers and Acquisitions, Segment by Value, 2008-2011
Figure 103: Cytotoxic Therapies Market, Global, Co-Development Deals, By Indication (%), 2008-2011
Figure 104: Cytotoxic Therapies Market, Global, Co-Development Deals, Segment by Year, 2008-2011
Figure 105: Cytotoxic Therapies Market, Global, Co-Development Deals, Segment by Geography (%), 2008-2011
Figure 106: Cytotoxic Therapies Market, Global, Licensing Deals, By Indication (%), 2008-2011
Figure 107: Cytotoxic Therapies Market, Global, Licensing Deals, Segment by Year, 2008-2011
Figure 108: Cytotoxic Therapies Market, Global, Licensing Deals, Segment by Value (%), 2008-2011
Figure 109: Cytotoxic Therapies Market, Global, Licensing Deals, Segment by Geography (%), 2008-2011
Figure 110: GBI Research Market Forecasting Model

Ordering:  
Order Online - http://www.researchandmarkets.com/reports/2130784/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Cytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion
Web Address: http://www.researchandmarkets.com/reports/2130784/
Office Code: SCD2LPNW

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Formats</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>USD 3500</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>USD 7000</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>USD 10500</td>
<td></td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [Mr] [Mrs] [Dr] [Miss] [Ms] [Prof]
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World